POXEL (PXXLF) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research cut shares of POXEL (OTCMKTS:PXXLF) from a buy rating to a hold rating in a report issued on Thursday morning.

According to Zacks, “Poxel SA is a biopharmaceutical company. It offers drugs for metabolic diseases such as diabetes and related metabolic disorders. The company’s product pipeline consists of Imeglimin, PXL770 and PXL007 which are in clinical trial stage. Poxel SA is headquartered in Lyon, France. “

Shares of OTCMKTS PXXLF remained flat at $$8.11 during trading on Thursday. 1,000 shares of the stock were exchanged. POXEL has a 12-month low of $8.11 and a 12-month high of $8.11.



TRADEMARK VIOLATION WARNING: “POXEL (PXXLF) Stock Rating Lowered by Zacks Investment Research” was originally published by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://dakotafinancialnews.com/2018/04/13/poxel-pxxlf-stock-rating-lowered-by-zacks-investment-research.html.

Get a free copy of the Zacks research report on POXEL (PXXLF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for POXEL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for POXEL and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply